Guardant Health, Inc. GH

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
53/100
Moderate

Ranked against 61 peers in Diagnostics & Research

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect … Full GH analysis →

Key strengths

  • Elite Gross Margins Gross margin quality is top-tier vs peers (score 0.77). This signals strong consumable attach-rate economics.
  • Improving FCF Trend FCF trend score is positive (score 0.78). Improving FCF margin signals compounding operational leverage.

Key risks

  • Weak Capital Return Profile Capital return quality is below peers (score 0.26). Low ROIC raises questions about M&A discipline and pipeline ROI.
  • Thin Interest Coverage Interest coverage lags peers (score 0.12). Thin coverage limits M&A optionality and raises refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Moderate
71
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where GH ranks in Diagnostics & Research

Guardant Health, Inc. ranks #29 of 62 scored companies in Diagnostics & Research by moat score — the top 47%. The widest moat in the group is IDEXX Laboratories, Inc. (IDXX) at 78/100.

# Company Moat score Rating
25 RadNet, Inc. RDNT 54/100 Moderate
26 Charles River Laboratories Inte CRL 54/100 Moderate
27 Natera, Inc. NTRA 54/100 Moderate
28 Precipio, Inc. PRPO 53/100 Moderate
29 Guardant Health, Inc. GH 53/100 Moderate
30 MDxHealth SA MDXH 51/100 Moderate
31 Biodesix, Inc. BDSX 51/100 Moderate
32 NeoGenomics, Inc. NEO 50/100 Developing
33 Prenetics Global Limited PRE 50/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How GH scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 71 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 43 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 53 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 50 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 12 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 58 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding GH's moat

What is Guardant Health, Inc.'s moat score?

Guardant Health, Inc. (GH) scores 53 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #29 of 62 scored companies in Diagnostics & Research, the top 47%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research. Its strongest defense is Pricing Power & Consumable Moat (71/100) and its weakest is Capital Structure & Resilience (12/100).

How does Guardant Health, Inc. compare with other Diagnostics & Research companies?

Guardant Health, Inc. ranks #29 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Precipio, Inc. (PRPO) at 53 just above it and MDxHealth SA (MDXH) at 51 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.

Why is Guardant Health, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Guardant Health, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and GH scores: Pricing Power & Consumable Moat (71), R&D Pipeline & Capital Returns (43), FCF Quality & Cash Conversion (53), Commercial Execution (50), Capital Structure & Resilience (12), Growth Durability (58). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000